RE:TD Previewretiredcf wrote: CRH reports a better-than-expected Q4/F20; some questions raised. Yesterday, CRH reported Q4 revenue of US$36.8mm (up 21% y/y and q/q) and Adj. EBITDA (to shareholders) of US$11.2mm (total Adj. EBITDA of $16.1mm; 43.8% margin), ahead of consensus at US$34.0mm and US$8.9mm, respectively. Patient cases were 108,681 in Q4, up 15% y/y and 16% q/q. We note that material weaknesses in internal controls over financial reporting were identified (could lead to material misstatements of its financial statements). Remediation measures are being implemented and we look to get more details as to the impact on WELL's pending acquisition, if any.
interesting - I can't seem to find a CRH conference call replay or transcript, maybe they didn't do one?
would be interested in learning more about this and any restatement of earnings...